Two medicines, side by side
Edoxaban vs rivaroxaban
Edoxaban and rivaroxaban are both labeled for atrial fibrillation, blood clots (DVT and PE) and stroke prevention. Drugs@FDA records approvals of edoxaban since 2015 and of rivaroxaban since 2011. Pharmacies paid $15.51 per Savaysa 60 mg tablet and $0.650 per rivaroxaban 2.5 mg tablet (NADAC, October 7, 2026); the strengths differ and one is a brand and one a generic, so the two prices are not like for like. Rivaroxaban's other strengths are brand-only: $19.54 per Xarelto 20 mg tablet. How each works, in its label's words: Edoxaban, “Edoxaban is a selective inhibitor of FXa.”; Rivaroxaban, “XARELTO is a selective inhibitor of FXa.”
Check it at the source: the edoxaban FDA label on DailyMed (effective July 10, 2025); the rivaroxaban FDA label on DailyMed (effective September 10, 2026).
Highlights of the edoxaban record
Edoxaban (Savaysa) · label of July 10, 2025
(A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA WARNING: (A) REDUCED EFFICACY IN NONVALVULAR ATRIAL FIBRILLATION PATIENTS WITH CREATININE CLEARANCE (CRCL) > 95 ML/MIN (B) PREMATURE DISCONTINUATION OF SAVAYSA INCREASES THE RISK OF ISCHEMIC EVENTS (C) SPINAL/EPIDURAL HEMATOMA See full prescribing information for complete boxed warning.
Used for
From the label: indicationsSAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the […]
On the market
- Earliest approval on file
- January 8, 2015
- Generic labelers
- none listed
- Pharmacy cost
- $15.51 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the rivaroxaban record
Rivaroxaban (Xarelto) · label of September 10, 2026
(A) PREMATURE DISCONTINUATION OF XARELTO INCREASES THE RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA A. Premature discontinuation of XARELTO increases the risk of thrombotic events Premature discontinuation of any oral anticoagulant, including XARELTO, increases the risk of thrombotic events.
Used for
From the label: indicationsXARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for […]
On the market
- Earliest approval on file
- July 1, 2011
- Generic labelers
- 20 labelers
- Pharmacy cost
- $0.650 per tablet
Supply and safety
- Shortage
- A presentation being discontinued
- Recalls
- 1
Source: FDA drug labels via openFDA (Edoxaban label of July 10, 2025, Rivaroxaban label of September 10, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do edoxaban and rivaroxaban differ on the record?
How each works, in its label's words: Edoxaban, “Edoxaban is a selective inhibitor of FXa.”; Rivaroxaban, “XARELTO is a selective inhibitor of FXa.”
Both are in FDA's class factor Xa inhibitors.
Half-life, in each label's words: Edoxaban, “The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours.”; Rivaroxaban, “The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years.”
Both labels carry a boxed warning; the records quote them.
Generics: edoxaban none approved; rivaroxaban since 2025 (Drugs@FDA).
| Edoxaban | Rivaroxaban | |
|---|---|---|
| Labeled for | Atrial fibrillation, Stroke prevention, Blood clots (DVT and PE) | Atrial fibrillation, Heart attack and coronary artery disease, Blood clots (DVT and PE), Stroke prevention |
| Pharmacologic class | Factor Xa Inhibitor | Factor Xa Inhibitor |
| How it works (label) | Edoxaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Edoxaban inhibits free FXa, and prothrombinase activity and inhibits thrombin-induced platelet aggregation. | XARELTO is a selective inhibitor of FXa. It does not require a cofactor (such as Anti-thrombin III) for activity. Rivaroxaban inhibits free FXa and prothrombinase activity. |
| Half-life (label) | The terminal elimination half-life of edoxaban following oral administration is 10 to 14 hours. | The terminal elimination half-life of rivaroxaban is 5 to 9 hours in healthy subjects aged 20 to 45 years. |
| Earliest approval on file (Drugs@FDA) | January 8, 2015 | July 1, 2011 |
| First generic approved | none | March 3, 2025 |
| Generic labelers (NDC) | none listed | 20 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $15.51 per tablet (Savaysa 60 mg tablet) | $0.650 per tablet (Rivaroxaban 2.5 mg tablet) |
| 12-month price change | +6% | -81% |
| Boxed warning | Yes | Yes |
| Shortage now | No current entry | A presentation being discontinued |
| Recalls recorded | 0 | 1 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 6,591 | 206,938 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Edoxaban label, drug interactionsLong-term concomitant treatment with SAVAYSA and other anticoagulants is not recommended because of increased risk of bleeding [see Warnings and Precautions (5.3) ].
Rivaroxaban label, drug interactionsAvoid concurrent use of XARELTO with other anticoagulants due to increased bleeding risk unless benefit outweighs risk.
Source: FDA drug labels via openFDA
What next?
- Alternatives to edoxaban
- every medicine labeled for the same conditions